The International Journal of Neuropsychopharmacology
April 19, 2015
Anna S. Höflich, Andreas Hahn, Martin Küblböck et al.
130 citations
BACKGROUND: Schizophrenia has been associated with disturbances of thalamic functioning. In light of recent evidence suggesting a significant impact of the glutamatergic system on key symptoms of schizophrenia, we assessed whether modulation of the glutamatergic system via blockage of the N-methyl-D-aspartate (NMDA)-receptor might lead to changes of thalamic functional connectivity. METHODS:...
Pharmacology
2003
Gudrun Wakonigg, Katja Sturm, Alois Saria et al.
Although ‘ecstasy’ (3,4-methylenedioxymethamphetamine, MDMA) is, after marijuana, the second most prevalent illegal drug of abuse in European adolescents, animal experimental evidence of MDMA’s reinforcing effect has remained scarce, particularly in the rodent model, raising questions about the robustness of MDMA’s reinforcing effect under controlled laboratory conditions. In the present rat...
Pharmacology
2001
Elisabeth Ratzenboeck, Alois Saria, Norbert Kriechbaum et al.
97 citations
3,4-Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) is one of the most prevalent illegal drugs of abuse among European adolescents, a population not generally experienced with respect to ‘hard’ drugs such as cocaine. We, therefore, determined the reinforcing effect of intravenously self-administered MDMA in a fixed ratio 1 time-out 150 s schedule of reinforcement in rats that were truly drug...
European Journal of Neuroscience
April 1, 2000
H. S. Fischer, Gerald Zernig, Dieter S. Schatz et al.
54 citations
Abstract The pharmacological basis of acute (±)‐MDMA (3,4‐methylenedioxymethamphetamine) intoxication still awaits full characterization. According to present knowledge, MDMA enhances the release of serotonin and dopamine in striatal slices and interacts with different types of receptors such as 5‐HT 2 (5‐hydroxytryptamine or serotonin), M 1 and M 2 muscarinic acetylcholine (ACh), and histamine...